Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BMS-986207 + Dexamethasone + Pomalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-986207||BMS986207|BMS 986207||Immune Checkpoint Inhibitor 98||BMS-986207 is a human monoclonal antibody against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which removes the immune checkpoint blockade by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155) (NCI Drug Dictionary).|
|Pomalidomide||Pomalyst||CC-4047||Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04150965||Phase Ib/II||Relatlimab BMS-986207 BMS-986207 + Dexamethasone + Pomalidomide Dexamethasone + Pomalidomide + Relatlimab Dexamethasone + Elotuzumab + Pomalidomide||Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT||Recruiting||USA||0|